摘要
肝内胆管癌(ICC)可切除率低,进展期ICC的治疗有效率不高,预后很差。转化治疗在多种晚期肿瘤中有一定的疗效,是目前晚期肿瘤治疗的研究热点。随着对ICC基因组的深入了解和新的治疗药物的开发及组合,基于系统化疗的联合治疗策略,精准靶向治疗,免疫检查点抑制剂等显示出较好的疗效,使得部分进展期ICC病人能降期转化手术,获得长期生存。
Intrahepatic cholangiocarcinoma(ICC) has a low resectable rate. The effect of treatment and the prognosis are poor in advanced ICC. Conversion therapy shows a certain effect in the advanced tumors. With the understanding of the ICC genome and the development of new therapeutic drugs,combined strategies based on systemic chemotherapy,biomarker-driven targeted therapy and immune checkpoint inhibitors have shown promising efficacy. As a result, some advanced ICC patients have gotten experienced downstaging and undergone conversion therapy to achieve long-term survival.
作者
赵海涛
杨旭
ZHAO Hai-tao;YANG Xu(Department of Liver Surgery,Peking Union Medical College Hospital,Beijing 100630,China)
出处
《中国实用外科杂志》
CSCD
北大核心
2020年第6期732-737,共6页
Chinese Journal of Practical Surgery
基金
国际科学技术合作项目(No.2016YFE0107100,No.2015DFA30650)
CAMS临床和转化医学研究基金(No.2019XK320006)
CAMS医学创新基金(CIFMS)(No.2017-I2M-4-003,No.2018-I2M-3-001)
卫生发展专项资金研究项目(No.2014-2-4012)
北京自然科学基金(No.L172055,No.7192158)
中央高校基本科研基金(No.3332018032)
国家万人计划。
关键词
肝内胆管癌
转化治疗
系统化疗
靶向治疗
免疫检查点抑制剂
in trahepatic cholangiocarcinoma
conversion therapy
systemic chemotherapy
targeted therapy
immune checkpoint inhibitors
